ADC Therapeutics SA (ADCT) - Net Assets
Based on the latest financial reports, ADC Therapeutics SA (ADCT) has net assets worth $-216.38 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($291.50 Million) and total liabilities ($507.87 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ADCT PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-216.38 Million |
| % of Total Assets | -74.23% |
| Annual Growth Rate | N/A |
| 5-Year Change | -211.89% |
| 10-Year Change | N/A |
| Growth Volatility | 137.53 |
ADC Therapeutics SA - Net Assets Trend (2016–2025)
This chart illustrates how ADC Therapeutics SA's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see ADCT market cap.
Annual Net Assets for ADC Therapeutics SA (2016–2025)
The table below shows the annual net assets of ADC Therapeutics SA from 2016 to 2025. Also explore ADCT shareholders equity momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-185.83 Million | +8.29% |
| 2024-12-31 | $-202.64 Million | -36.69% |
| 2023-12-31 | $-148.25 Million | -286.59% |
| 2022-12-31 | $79.45 Million | -52.16% |
| 2021-12-31 | $166.09 Million | -50.50% |
| 2020-12-31 | $335.50 Million | +201.83% |
| 2019-12-31 | $111.16 Million | -11.95% |
| 2018-12-31 | $126.24 Million | -49.33% |
| 2017-12-31 | $249.17 Million | +76.85% |
| 2016-12-31 | $140.89 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ADC Therapeutics SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 151681400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $11.08 Million | % |
| Other Comprehensive Income | $-517.00K | % |
| Other Components | $1.44 Billion | % |
| Total Equity | $-185.83 Million | 100.00% |
ADC Therapeutics SA Competitors by Market Cap
The table below lists competitors of ADC Therapeutics SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Group Eleven Resources Corp
V:ZNG
|
$143.74 Million |
|
SRV YHTIOET OYJ
F:B7J1
|
$143.76 Million |
|
Bny Mellon Municipal Income Inc
NYSE MKT:DMF
|
$143.85 Million |
|
Bulten AB
ST:BULTEN
|
$143.88 Million |
|
IZMO Limited
NSE:IZMO
|
$143.72 Million |
|
Limes Schlosskliniken AG
XETRA:LIK
|
$143.66 Million |
|
Emmerson Resources Ltd
AU:ERM
|
$143.62 Million |
|
Hyloris Developmentsen Sa
BR:HYL
|
$143.38 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ADC Therapeutics SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -202,642,000 to -185,834,000, a change of 16,808,000.
- Net loss of 142,623,000 reduced equity.
- New share issuances of 86,282,000 increased equity.
- Other comprehensive income increased equity by 904,000.
- Other factors increased equity by 72,245,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-142.62 Million | -76.75% |
| Share Issuances | $86.28 Million | +46.43% |
| Other Comprehensive Income | $904.00K | +0.49% |
| Other Changes | $72.25 Million | +38.88% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares ADC Therapeutics SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $4.23 | $1.23 | x |
| 2018-12-31 | $2.35 | $1.23 | x |
| 2019-12-31 | $1.66 | $1.23 | x |
| 2020-12-31 | $5.13 | $1.23 | x |
| 2021-12-31 | $2.16 | $1.23 | x |
| 2022-12-31 | $1.02 | $1.23 | x |
| 2023-12-31 | $-1.81 | $1.23 | x |
| 2024-12-31 | $-2.09 | $1.23 | x |
| 2025-12-31 | $-1.46 | $1.23 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ADC Therapeutics SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -175.31%
- • Asset Turnover: 0.25x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-72.00%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -36.07% | -4984.03% | 0.01x | 1.09x | $-114.78 Million |
| 2018 | -97.51% | -10797.89% | 0.01x | 1.19x | $-135.72 Million |
| 2019 | -104.79% | -4977.95% | 0.02x | 1.24x | $-127.60 Million |
| 2020 | -73.41% | 0.00% | 0.00x | 1.53x | $-279.84 Million |
| 2021 | -138.50% | -678.20% | 0.05x | 3.72x | $-246.63 Million |
| 2022 | -197.77% | -74.86% | 0.43x | 6.18x | $-165.07 Million |
| 2023 | 0.00% | -345.11% | 0.20x | 0.00x | $-225.23 Million |
| 2024 | 0.00% | -222.83% | 0.22x | 0.00x | $-137.58 Million |
| 2025 | 0.00% | -175.31% | 0.25x | 0.00x | $-124.04 Million |
Industry Comparison
This section compares ADC Therapeutics SA's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $273,434,633
- Average return on equity (ROE) among peers: -9.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $-216.38 Million | -36.07% | N/A | $143.73 Million |
| Aurora Cannabis Inc (ACB) | $1.56 Billion | 4.60% | 0.21x | $236.15 Million |
| Akanda Corp (AKAN) | $-2.20 Million | 0.00% | 0.00x | $1.39 Million |
| Akebia Ther (AKBA) | $-2.68 Million | 0.00% | 0.00x | $237.37 Million |
| Alkermes Plc (ALKS) | $162.85 Million | -41.79% | 0.31x | $6.84 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-151.17 Million | 0.00% | 0.00x | $3.26 Billion |
| Amphastar P (AMPH) | $364.36 Million | -1.57% | 0.41x | $980.07 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $896.36 Million | -18.93% | 3.86x | $5.92 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $-375.58 Million | 0.00% | 0.00x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $5.40 Million | -25.93% | 0.43x | $266.92 Million |
About ADC Therapeutics SA
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatme… Read more